Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Hydrochloride, Nogitecan

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

19 API Suppliers, 6 USDMF, 1 JDMF, 4 KDMF, 3 NDC API, 12 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

64 Drugs in Development

64 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

92 FDF Dossiers, 22 FDA Orange Book, 51 Europe, 5 Canada, 4 Australia, 4 South Africa, 6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;INTRAVENOUS - EQ 1MG BASE/ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML), INJECTABLE;INJECTION - EQ 4MG BASE/VIAL, CAPSULE;ORAL - EQ 0.25MG BASE, CAPSULE;ORAL - EQ 1MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 6 DKSH, 1 Gangwal Healthcare, 1 Pfanstiehl, 1 Capital Farma, 4 ACG Worldwide, 1 Actylis, 2 BASF, 1 CD Formulation, 3 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 1 Kerry, 3 Lonza Capsugel, 2 Microlex e.U, 1 Pluviaendo, 1 Qualicaps, 5 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

21 Fillers, Diluents & Binders, 12 Chewable & Orodispersible Aids, 11 Taste Masking, 10 Direct Compression, 8 Empty Capsules, 7 Disintegrants & Superdisintegrants, 6 Thickeners and Stabilizers, 6 Coating Systems & Additives, 5 Parenteral, 5 Solubilizers, 3 Granulation, 3 Co-Processed Excipients, 2 Film Formers & Plasticizers, 2 Topical, 2 Coloring Agents, 1 Controlled & Modified Release

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 21 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 12 Regulatory FDF Prices

MARKET PLACE

5 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 Health Canada Patents

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	ScinoPharm Taiwan Ltd	Taiwan	Korea United Pharmaceutical Co., Ltd.	20120703-207-I-40-01(1)	topotecan hydrochloride	2016-03-02	ScinoPharm Taiwan, Ltd	Taiwan	No. 1, Nan-Ke 8th Road, Tainan Science-Based Industrial Park, Shan-Hua, Tainan 74144_x000D_
29/11/2025	ScinoPharm Taiwan Ltd	Taiwan	Alvogen Korea Co., Ltd.	20120703-207-I-40-01	topotecan hydrochloride	2012-07-03	ScinoPharm Taiwan, Ltd	Taiwan	No.1 Nan-Ke 8th Road Shan-Hua, Tainan 74144, Taiwan

Hydrochloride, Nogitecan

Hydrochloride, Nogitecan

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

19 API Suppliers

6 USDMF

1 JDMF

4 KDMF

3 NDC API

12 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

64 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

92 FDF Dossiers

22 FDA Orange Book

51 Europe

5 Canada

4 Australia

4 South Africa

6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;INTRAVENOUS - EQ 1MG BASE/ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

INJECTABLE;INJECTION - EQ 4MG BASE/VIAL

CAPSULE;ORAL - EQ 0.25MG BASE

CAPSULE;ORAL - EQ 1MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

14 SPI Pharma

6 DKSH

1 Gangwal Healthcare

1 Pfanstiehl

1 Capital Farma

4 ACG Worldwide

1 Actylis

2 BASF

1 CD Formulation

3 Gangwal Chemicals

1 Ingredion Pharma Solutions

1 Kerry

3 Lonza Capsugel

2 Microlex e.U

1 Pluviaendo

1 Qualicaps

5 Roquette

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

21 Fillers, Diluents & Binders

12 Chewable & Orodispersible Aids

11 Taste Masking

10 Direct Compression

8 Empty Capsules

7 Disintegrants & Superdisintegrants

6 Thickeners and Stabilizers

6 Coating Systems & Additives

5 Parenteral

5 Solubilizers

3 Granulation

3 Co-Processed Excipients

2 Film Formers & Plasticizers

2 Topical

2 Coloring Agents

1 Controlled & Modified Release

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

21 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions

12 Regulatory FDF Prices

MARKET PLACE

SOLUTION;INTRAVENOUS - EQ 1MG BASE/ML (EQ 1MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - EQ 3MG BASE/3ML (EQ 1MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons